Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + oxaliplatin + fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Seoul National University Bundang Hospital
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intravenous
01
Overview
This investigational combination chemotherapy regimen, evaluated by Seoul National University Bundang Hospital, is designed for the treatment of stage IV gastric cancer with peritoneal carcinomatosis. The regimen, known as IPLUS, consists of intraperitoneal (IP) paclitaxel combined with systemic mFOLFOX6 (modified oxaliplatin, fluorouracil, and leucovorin). Paclitaxel is a small molecule taxane that stabilizes microtubules, thereby inhibiting cell division. By administering paclitaxel intraperitoneally, the treatment achieves high local concentrations directly within the peritoneal cavity to target metastatic disease, while the systemic mFOLFOX6 component—comprising the platinum-based alkylating agent oxaliplatin, the thymidylate synthase inhibitor fluorouracil, and the biochemical modulator leucovorin—addresses systemic disease. This dual-delivery approach aims to improve outcomes in patients with advanced gastric adenocarcinoma and peritoneal metastasis.
- Other names
- IP Paclitaxel + mFOLFOX6Intraperitoneal Paclitaxel + mFOLFOX6Intraperitoneal Paclitaxel with Systemic mFOLFOX6
02
Targets
TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on paclitaxel + oxaliplatin + fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + oxaliplatin + fluorouracil + leucovorin.